InSite Vision is engaged in the advancement of new ophthalmologic products to address unmet eye care needs. The company’s DuraSite and DuraSite 2 drug delivery systems extend drug retention duration on the surface of the eye, reducing the frequency of treatment and improving topical drug efficacy. InSite Vision’s DuraSite platform is currently leveraged in two commercial products, AzaSite and Besivance, and the company is advancing three novel ophthalmic therapeutics through Phase 3 clinical studies. For more information, visit the company’s Web site: http://www.insitevision.com
Let us hear your thoughts below:
